ANP.AX - Antisense Therapeutics Limited

ASX - ASX Delayed Price. Currency in AUD

Antisense Therapeutics Limited

6-8 Wallace Avenue
Toorak, VIC 3142
61 3 9827 8999

IndustryDrug Manufacturers - Major
Full Time Employees9

Key Executives

Mr. Mark Diamond BSc, MBA, MAICDCEO, MD & DirectorN/AN/AN/A
Mr. Phillip Allen Hains BBus(Acc), MBA, CACFO & Company Sec.N/AN/A59
Dr. George TachasDirector of Drug Discovery & PatentsN/AN/AN/A
Susan TurnerFin. & Admin. Mang.N/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Antisense Therapeutics Limited engages in the research and development of antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor for prostate cancer treatment. Its product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as a potential treatment for diseases associated with excessive growth hormone action. The company is based in Toorak, Australia.

Corporate Governance

Antisense Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.